The Future of TB in the United States: Going, or Growing?
TAGline • 2012By Erica Lessem This summer, Treatment Action Group (TAG) and its partners in fighting tuberculosis (TB) issued a call for zero TB deaths, zero new TB infections, and zero suffering from TB. Yet the U.S., long a leader in TB elimination efforts, is in jeopardy of losing ground in the struggle to get to zero.…
Hepatitis C Drug Development Goes from Pony Ride to Rocket Launch
Pipeline • 2012December 2012 Update – Cure rates presented at the American Association for the Study of Liver Diseases (AASLD) July 2012 By Tracy Swan and Karyn Kaplan Dedicated to Michael Carden A fabulous, kind, brilliant, and hilarious friend and colleague 1971–2012 Special thanks to Jules Levin Introduction Hepatitis C virus (HCV) infection is curable, although it…
Does Obama’s 2013 Budget Herald the End of PEPFAR?
TAGline • 2012Devastating Funding Proposal Undermines the Global Fight Against AIDS by Coco Jervis A sense of disbelief washed over the global AIDS community last month when President Obama unveiled his fiscal year 2013 budget proposal to cut $563 million from the President’s Emergency Plan for AIDS Relief (PEPFAR) program. Cuts of this magnitude could lead to…
The Tuberculosis Treatment Pipeline
Pipeline • 2012Updates to this chapter can be found in the postscript at the end of this page. Original Report July 2012 By Erica Lessem Introduction Tuberculosis (TB) persists as a global health problem, suffering from both insufficient funding and political will. As a result of poor treatment options and inadequate administration of care, increasingly intractable drug-resistant…
Hepatitis C Treatment Access: Spotlight on Thailand/Asia
Pipeline • 2012July 2012 By Karyn Kaplan According to the Universal Declaration of Human Rights and subsequent treaties, all people have a fundamental right to the highest attainable standard of health, as well as a right to the benefits of scientific progress and its applications. Yet many governments in the global South are unable to even progressively…
Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies
Pipeline • 2012Selected updates to this chapter will be posted below prior to the 2013 edition of the Pipeline Report. Feburary 2013 Update Additional clinical trials in the Research Toward a Cure/Therapeutic Vaccines/Gene Therapies categories: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma Estimated Enrollment: 13 Fred Hutchinson Cancer…
The Pediatric Antiretroviral Pipeline
Pipeline • 2012By Polly Clayden NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2012. In the past year—since our last Pipeline Report—there has been a flurry of activity in pediatric antiretroviral drug development and approval. While overall the pipeline for children looks encouraging, the short- and medium-term requirements…
The Antiretroviral Pipeline
Pipeline • 2012July 2012 By Simon Collins NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2012. Updates from CROI 2013. (March 2013) at the end of this article. INTRODUCTION Two aspects of antiretroviral treatment over the last year have developed along separate paths despite their clear connection. The…
Introduction and Executive Summary
Pipeline • 2012July 2012 By Polly Clayden and Mark Harrington In nine countries, we enrolled 1763 couples in which one partner was HIV-1–positive and the other was HIV-1–negative; 54% of the subjects were from Africa, and 50% of infected partners were men. HIV-1–infected subjects with CD4 counts between 350 and 550 cells per cubic millimeter were randomly…
Micardis Sign-on Letter to Boehringer Ingelheim
Letters • 2012Letter urging the company to reconsider its negative decision to provide free telmisartan (Micardis) and matching placebo to the AIDS Clinical Trials Group so that it may move forward with Study A5317.